dual IRAK1/4 inhibitor R906289 monosodium

{
  "id": "MLC-T-ONC-013176",
  "term": "dual IRAK1/4 inhibitor R906289 monosodium",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, monosodium salt form of R906289, a prodrug of R835, a small molecule inhibitor of interleukin-1 receptor-associated kinases 1 (IRAK1) and 4 (IRAK4), with potential immunomodulating and anti-inflammatory activities. Upon oral administration, R906289 is converted to its active metabolite R835. R835 targets, binds to, and inhibits the activity of IRAK1 and IRAK4. This inhibits lipopolysaccharide (LPS)/Toll-like receptor 4 (TLR4) signaling and LPS/TLR4-induced proinflammatory cytokine production. This may inhibit inflammation and immune-mediated cell destruction in inflammatory and auto-immune diseases where TLR or interleukin 1 receptor (IL-1R) signaling is overactivated. IRAK1 and IRAK4, serine/threonine-protein kinases, play key roles in signaling downstream of TLR and IL-1R, and TLR/IL-1R-induced production of proinflammatory cytokines.",
  "synonyms": [
    "IRAK1/4 inhibitor R289 Na",
    "R289 Na",
    "R906289 monosodium"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dual-irak1-4-inhibitor-r906289-monosodium/"
}